A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas

Journal of B.U.ON.

Volumn 9, Issue 3, 2004, Pages 263-267

  Karacetin, Didem ^a   Incekara, O ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Cisplatin; Epirubicin; Etoposide; Gastric cancer

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; POSTOPERATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; VOMITING;

EID: 14944350273     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: Metaanalysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447.
2. Murad AM, Santiago FF, Perroiand A. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37-41.
3. Wils J, Klein HO, Wagener DJ et al. Sequential high dose methotrexate and 5 fluorouracil combined with doxorubicin; a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9: 827-831.
4. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer. Br J Cancer 1999; 804: 259-272.
5. Cocconi G, Bella M, Zironi S, Algrei L et al. Fluorouracil, doxorubicin, and mitomycin C combination versus PELF chemotherapy in advanced gastric cancer; a prospective randomized trial of the Oncology Group for Clinical Research. J Clin Oncol 1994; 12: 2687-2693.
6. Vezerdis MP, Wanebo HJ. Gastric cancer: surgical approach. In: Ahlgreen JD, MacDonald JS (eds): Gastrointestinal Oncology. Philadelphia, PA, JB Lippincott, 1992, pp 159-170.
7. Bonenkamp JJ, Hermans J, Sasako M et al. Extended lymph node dissection for gastric cancer. N Engl J Med 1999; 340: 908-914.
8. McDonald JS, Fleming TR, Peterson RF et al. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Souhwest Oncology Group study. Ann Surg Oncol 1995; 2: 488-494.
9. Comis RL, Carter SK. Integration of chemotherapy into combined modality treatment of solid tumors. III. Gastric cancer. Cancer Treatment Rev 1974; 1: 221-222.
10. Schein PS, Smith FP, Woolley PV, Ahlgren JD. Current management of advanced and locally unresectable gastric carcinoma. Cancer 1982; 50: 2590-2593.
11. Woolley PV, Smith F, Estevez R. A phase II trial of 5-FU, adriamycin, and cisplatin in advanced gastric carcinoma. Proc Am Soc Clin Oncol 1981; 22: 445 (abstr).
12. Douglass H, Lavin Pt, Goudsmit A, Klaassen DJ. Phase I-II evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin and 5-FU in advanced measurable gastric cancer. Proc Am Soc Clin Oncol 1983; 2: 121 (abstr).
13. Benetta G, Fraschini P, Labianca R, Luporini G. The value of FAM chemotherapy in advanced gastric cancer. Proc Am Soc Clin Oncol 1982; 1: 103 (abstr).
14. Moertel CG, Rubin J, O'Connell MJ et al. A phase II study of combined 5 fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053-1054.
15. Rougier P, Droz JP, Theodore C et al. Phase II trial of combined 5 fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma. Cancer Treat Rep 1987; 71: 1301-1304.
16. John S, McDonald MD. Gastric Cancer. Educational Book of the American Society of Clinical Oncology 2001; pp 77-80.
17. Cullinan S, Moertel C, Fleming T et al. A randomized comparison of 5-FU alone, 5-FU+adriamycin+mitomycin C (FAM) in gastric and pancreatic cancer. Proc Am Soc Clin Oncol 1984; 12: 137 (abstr).
18. Bruckner HW, Lokich JJ, Stablein DM. Studies of Baker's antifol, methotrexate in advanced gastric cancer. A Gastrointestinal Tumor Study Group Report. Cancer Treat Rep 1982; 66: 1713-1717.
19. Taal BG, ten Bokkel Huinink WW, Simonetti G, Franklin H, McVie JG. A phase II trial of sequential MTX and 5FU alternated with epidoxorubicin and cisplatin in advanced gastric cancer. Cancer Invest 1990; 8: 501-504.